Compare Citius Pharmaceuticals Inc (CTXR) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ulta Beauty Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Ulta Beauty Inc trades at $469.56 (market cap $20.17B). The key difference: Ulta Beauty Inc is far larger — about 1377.7× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| CTXR | ULTA | |
|---|---|---|
Market Cap | $14.64M | $20.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $706.82 |
52-Week Low | $0.53 | $450.75 |
Enterprise Value | $10.86M | $22.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
ULTA trades at $473.33, up 0.88% today, with a bullish technical signal despite mixed moving averages. The company reported Q1 2026 EPS of $7.74, beating expectations, and maintains strong profitability with a 39.33% gross margin and 47.45% ROE. Recent news highlights international expansion and a partnership with Bath & Body Works, while analyst consensus remains strongly positive with a $623.73 price target.
ULTA presents a compelling investment case with robust fundamentals and growth initiatives, though risks include competitive pressures and potential margin compression. The stock's current valuation below analyst targets suggests upside potential, supported by strong loyalty program engagement and strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
